Rajan Saju, Vyas Dinesh, Clark Andrew T, Woolsey Cheryl A, Clark Jessica A, Hotchkiss Richard S, Buchman Timothy G, Coopersmith Craig M
Department of Surgery, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
Shock. 2008 Apr;29(4):483-9. doi: 10.1097/shk.0b013e31815bbb26.
Targeted IL-10 therapy improves survival in preclinical models of critical illness, and intestine-specific IL-10 decreases inflammation in models of chronic Inflammatory disease. We therefore sought to determine whether intestine-specific overexpression of IL-10 would improve survival in sepsis. Transgenic mice that overexpress IL-10 in their gut epithelium (Fabpi-IL-10 mice) and wild-type (WT) littermates (n = 127) were subjected to cecal ligation and puncture with a 27-gauge needle. The 7-day survival rate was 45% in transgenic animals and 30% in WT animals (P < or = 0.05). Systemic levels of IL-10 were undetectable in both groups of animals under basal conditions and were elevated to a similar degree in septic animals regardless of whether they expressed the transgene. Local parameter of injury, including gut epithelial apoptosis, intestinal permeability, peritoneal lavage cytokines, and stimulated cytokines from intraepithelial lymphocytes, were similar between transgenic and WT mice. However, in stimulated splenocytes, proinflammatory cytokines monocyte chemoattractant protein 1 (189 +/- 43 vs. 40 +/- 8 pg/mL) and IL-6 (116 +/- 28 vs. 34 +/- 9 pg/mL) were lower in Fabpi-IL-10 mice than WT littermates despite the intestine-specific nature of the transgene (P < 0.05). Cytokine levels were similar in blood and bronchoalveolar lavage fluid between the 2 groups, as were circulating LPS levels. Transgenic mice also had lower white blood cell counts associated with lower absolute neutrophil counts (0.5 +/- 0.1 vs. 1.0 +/- 0.2 10(3)/mm3; P < 0.05). These results indicate that gut-specific overexpression of IL-10 improves survival in a murine model of sepsis, and interactions between the intestinal epithelium and the systemic immune system may play a role in conferring this survival advantage.
靶向白细胞介素-10疗法可提高危重病临床前模型的生存率,肠道特异性白细胞介素-10可减轻慢性炎症性疾病模型中的炎症。因此,我们试图确定白细胞介素-10的肠道特异性过表达是否能提高脓毒症的生存率。在肠道上皮细胞中过表达白细胞介素-10的转基因小鼠(Fabpi-IL-10小鼠)和野生型(WT)同窝小鼠(n = 127)接受了用27号针头进行的盲肠结扎和穿刺。转基因动物的7天生存率为45%,野生型动物为30%(P≤0.05)。在基础条件下,两组动物的全身白细胞介素-10水平均检测不到,脓毒症动物中无论是否表达转基因,白细胞介素-10水平均升高至相似程度。转基因小鼠和野生型小鼠之间的局部损伤参数,包括肠道上皮细胞凋亡、肠道通透性、腹腔灌洗细胞因子以及上皮内淋巴细胞刺激产生的细胞因子相似。然而,在刺激的脾细胞中,尽管转基因具有肠道特异性,但Fabpi-IL-10小鼠中的促炎细胞因子单核细胞趋化蛋白1(189±43对40±8 pg/mL)和白细胞介素-6(116±28对34±9 pg/mL)低于野生型同窝小鼠(P<0.05)。两组之间血液和支气管肺泡灌洗液中的细胞因子水平相似,循环脂多糖水平也相似。转基因小鼠的白细胞计数也较低,绝对中性粒细胞计数也较低(0.5±0.1对(1.0±0.2)×10³/mm³;P<0.05)。这些结果表明,白细胞介素-10的肠道特异性过表达可提高脓毒症小鼠模型的生存率,肠道上皮与全身免疫系统之间的相互作用可能在赋予这种生存优势中发挥作用。